LINC01787: A Potential Drug Target and Biomarker (G101928241)

Target Name: LINC01787

NCBI ID: G101928241

LINC01787

Other Name(s): Long intergenic non-protein coding RNA 1787 | long intergenic non-protein coding RNA 1787

LINC01787: A Potential Drug Target and Biomarker

Non-protein coding RNAs (ncRNAs) have emerged as a promising area of research in recent years, with many studies highlighting their involvement in various biological processes. One such RNA, LINC01787, has shown promising potential as a drug target and biomarker in various cellular and biological processes. In this article, we will explore the biology and potential utility of LINC01787 as a drug target and biomarker.

The LINC01787 RNA

LINC01787 is a non-protein coding RNA that was identified in the LIC01787 gene, located on chromosome 16, at position 787. It is a small RNA molecule that contains 199 nucleotides and has a unique 5'-end and 3'-end, as well as a stem-loop structure in the middle. LINC01787 is expressed in various tissues and cellular processes, including the brain, heart, and gastrointestinal tract, and has been shown to play a role in various biological processes, including cell signaling, stem cell maintenance, and tissue repair.

The Potential Drug Target

One of the most promising aspects of LINC01787 is its potential as a drug target. LINC01787 has been shown to interact with various protein molecules, including the protein tyrosine kinase (PTK) signaling pathway, which is a critical pathway involved in many cellular processes, including cell growth, differentiation, and survival. PTK signaling is a highly validated target for many drugs, including anti-cancer drugs, and LINC01787 has been shown to be a potential drug target in various cellular processes.

In addition, LINC01787 has been shown to play a role in the regulation of cellular apoptosis, which is a natural mechanism of cell death that helps prevent damaged cells from accumulating and contributing to disease. LINC01787 has been shown to regulate the expression of genes involved in cell apoptosis, which suggests that it may be a potential drug target for diseases that are characterized by uncontrolled cell growth, such as cancer.

The Potential Biomarker

LINC01787 has also been shown to be a potential biomarker for several diseases, including cancer. One of the most promising aspects of LINC01787 as a biomarker is its ability to be downregulated in cancer cells, which suggests that it may be a potential therapeutic target for cancer. LINC01787 has been shown to be downregulated in various types of cancer, including breast, lung, and ovarian cancer, and has been shown to be involved in the regulation of cellular processes that are critical for cancer cell growth and survival.

In addition, LINC01787 has also been shown to be involved in the regulation of cellular angiogenesis, which is the process by which new blood vessels are formed in the body. LINC01787 has been shown to play a role in the regulation of angiogenesis, which suggests that it may be a potential biomarker for diseases characterized by abnormal angiogenesis, such as cancer.

Conclusion

In conclusion, LINC01787 is a promising non-protein coding RNA that has shown potential as a drug target and biomarker. Its unique 5'-end and 3'-end, as well as stem-loop structure and its interaction with various protein molecules, suggest that it may be a good candidate for drug targeting. Its role in the regulation of cell apoptosis and angiogenesis also suggests that it may be a potential biomarker for diseases characterized by abnormal cellular processes. Further research is needed to fully understand the potential utility of LINC01787 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1787

The "LINC01787 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01787 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets